Combination therapy with rituximab and allogeneic natural killer cells in -Hodgkin's lymphoma
Phase 1
Recruiting
- Conditions
- Relapsed/refractory non-Hodgkin's lymphoma.Other and unspecified types of non-Hodgkin lymphoma
- Registration Number
- IRCT20230801058996N6
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Patients with non-Hodgkin's lymphomas with the origin of B lymphocytes confirmed based on WHO criteria and clinical and paraclinical evidence
Patients with non-response or insufficient response to the first stage of treatment based on clinical and paraclinical evidence
Patients with disease recurrence
Patients with ECOG index of 0-2
Exclusion Criteria
Non-Hodgkin's B-cell lymphomas Patients with clinical and paraclinical full recovery
Non-Hodgkin's B-cell lymphomas Patients with clinical and paraclinical appropriate response to the first stage of treatment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method